Brian K Kit1, Elena Kuklina2, Margaret D Carroll3, Yechiam Ostchega3, David S Freedman4, Cynthia L Ogden3. 1. US Public Health Service, Rockville, Maryland2Division of Health and Nutrition Examination Surveys, National Center for Health Statistics, Centers for Disease Control and Prevention, Hyattsville, Maryland. 2. Division for Heart Disease and Stroke Prevention, National Center for Chronic Disease Prevention and Health Promotion, Atlanta, Georgia. 3. Division of Health and Nutrition Examination Surveys, National Center for Health Statistics, Centers for Disease Control and Prevention, Hyattsville, Maryland. 4. Division of Nutrition, Physical Activity, and Obesity, National Center for Chronic Disease Prevention and Health Promotion, Atlanta, Georgia.
Abstract
IMPORTANCE: Recent national data suggest there were improvements in serum lipid concentrations among US children and adolescents between 1988 and 2010 but an increase in or stable blood pressure (BP) during a similar period. OBJECTIVE: To describe the prevalence of and trends in dyslipidemia and adverse BP among US children and adolescents. DESIGN: The National Health and Nutrition Examination Survey, a cross-sectional survey. SETTING: Noninstitutionalized US population. PARTICIPANTS: Children and adolescents aged 8 to 17 years with measured lipid concentrations (n = 1482) and BP (n = 1665). MAIN OUTCOMES AND MEASURES: Adverse concentrations of total cholesterol (TC) (≥ 200 mg/dL), high-density lipoprotein cholesterol (HDL-C) (<40 mg/dL), and non-HDL-C (≥ 145 mg/dL) (to convert TC, HDL-C, and non-HDL-C to millimoles per liter, multiply by 0.0259) and high or borderline BP were examined. Definitions of BP were informed by the Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents by the National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. Analyses of linear trends in dyslipidemias and BP were conducted overall and separately by sex across 7 periods (1999-2000, 2001-2002, 2003-2004, 2005-2006, 2007-2008, 2009-2010, and 2011-2012). RESULTS: In 2011-2012, 20.2% (95% CI, 16.3-24.6) of youths had an adverse concentration of TC, HDL-C, or non-HDL-C and 11.0% (95% CI, 8.8-13.4) had either high or borderline BP. The prevalences of adverse concentrations decreased between 1999-2000 and 2011-2012 for TC (10.6% [95% CI, 8.3-13.2] vs 7.8% [95% CI, 5.7-10.4]; P = .006), HDL-C (17.9% [95% CI, 15.0-21.0] vs 12.8% [95% CI, 9.8-16.2]; P = .003), and non-HDL-C (13.6% [95% CI, 11.3-16.2] vs 8.4% [95% CI, 5.9-11.5]; P < .001). There was a decrease in high BP between 1999-2000 (3.0% [95% CI, 2.0-4.3]) and 2011-2012 (1.6% [95% CI, 1.0-2.4]) (P = .003). There was no change from 1999-2000 to 2011-2012 in borderline high BP (7.6% [95% CI, 5.8-9.8] vs 9.4% [95% CI, 7.2-11.9]; P = .90) or either high or borderline high BP (10.6% [8.4-13.1] vs 11.0% [95% CI, 8.8-13.4]; P = .26). CONCLUSIONS AND RELEVANCE: In 2011-2012, approximately 1 in 5 children and adolescents aged 8 to 17 years had an adverse lipid concentration of TC, HDL-C, or non-HDL-C and slightly more than 1 in 10 had either borderline high or high BP. The prevalence of dyslipidemia modestly decreased between 1999-2000 and 2011-2012, but either high or borderline high BP remained stable. The reasons for these trends require further study.
IMPORTANCE: Recent national data suggest there were improvements in serum lipid concentrations among US children and adolescents between 1988 and 2010 but an increase in or stable blood pressure (BP) during a similar period. OBJECTIVE: To describe the prevalence of and trends in dyslipidemia and adverse BP among US children and adolescents. DESIGN: The National Health and Nutrition Examination Survey, a cross-sectional survey. SETTING: Noninstitutionalized US population. PARTICIPANTS: Children and adolescents aged 8 to 17 years with measured lipid concentrations (n = 1482) and BP (n = 1665). MAIN OUTCOMES AND MEASURES: Adverse concentrations of total cholesterol (TC) (≥ 200 mg/dL), high-density lipoprotein cholesterol (HDL-C) (<40 mg/dL), and non-HDL-C (≥ 145 mg/dL) (to convert TC, HDL-C, and non-HDL-C to millimoles per liter, multiply by 0.0259) and high or borderline BP were examined. Definitions of BP were informed by the Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents by the National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. Analyses of linear trends in dyslipidemias and BP were conducted overall and separately by sex across 7 periods (1999-2000, 2001-2002, 2003-2004, 2005-2006, 2007-2008, 2009-2010, and 2011-2012). RESULTS: In 2011-2012, 20.2% (95% CI, 16.3-24.6) of youths had an adverse concentration of TC, HDL-C, or non-HDL-C and 11.0% (95% CI, 8.8-13.4) had either high or borderline BP. The prevalences of adverse concentrations decreased between 1999-2000 and 2011-2012 for TC (10.6% [95% CI, 8.3-13.2] vs 7.8% [95% CI, 5.7-10.4]; P = .006), HDL-C (17.9% [95% CI, 15.0-21.0] vs 12.8% [95% CI, 9.8-16.2]; P = .003), and non-HDL-C (13.6% [95% CI, 11.3-16.2] vs 8.4% [95% CI, 5.9-11.5]; P < .001). There was a decrease in high BP between 1999-2000 (3.0% [95% CI, 2.0-4.3]) and 2011-2012 (1.6% [95% CI, 1.0-2.4]) (P = .003). There was no change from 1999-2000 to 2011-2012 in borderline high BP (7.6% [95% CI, 5.8-9.8] vs 9.4% [95% CI, 7.2-11.9]; P = .90) or either high or borderline high BP (10.6% [8.4-13.1] vs 11.0% [95% CI, 8.8-13.4]; P = .26). CONCLUSIONS AND RELEVANCE: In 2011-2012, approximately 1 in 5 children and adolescents aged 8 to 17 years had an adverse lipid concentration of TC, HDL-C, or non-HDL-C and slightly more than 1 in 10 had either borderline high or high BP. The prevalence of dyslipidemia modestly decreased between 1999-2000 and 2011-2012, but either high or borderline high BP remained stable. The reasons for these trends require further study.
Authors: Vladimir Vuksan; Alexander Rogovik; Alexandra Jenkins; Valentina Peeva; Uljana Beljan-Zdravkovic; Mark Stavro; Christopher Fairgrieve; Sudi Devanesen; Amir Hanna; William Watson Journal: Paediatr Child Health Date: 2012-01 Impact factor: 2.253
Authors: Yechiam Ostchega; Margaret Carroll; Ronald J Prineas; Margaret A McDowell; Tatiana Louis; Tim Tilert Journal: Am J Hypertens Date: 2008-11-27 Impact factor: 2.689
Authors: Olli T Raitakari; Markus Juonala; Mika Kähönen; Leena Taittonen; Tomi Laitinen; Noora Mäki-Torkko; Mikko J Järvisalo; Matti Uhari; Eero Jokinen; Tapani Rönnemaa; Hans K Akerblom; Jorma S A Viikari Journal: JAMA Date: 2003-11-05 Impact factor: 56.272
Authors: Katherine J Overwyk; Lixia Zhao; Zefeng Zhang; Jennifer L Wiltz; Elizabeth K Dunford; Mary E Cogswell Journal: Hypertension Date: 2019-06-24 Impact factor: 10.190
Authors: Wei Perng; Deborah J Watkins; Alejandra Cantoral; Adriana Mercado-García; John D Meeker; Martha Maria Téllez-Rojo; Karen E Peterson Journal: Environ Res Date: 2017-01-31 Impact factor: 6.498
Authors: Emelia J Benjamin; Michael J Blaha; Stephanie E Chiuve; Mary Cushman; Sandeep R Das; Rajat Deo; Sarah D de Ferranti; James Floyd; Myriam Fornage; Cathleen Gillespie; Carmen R Isasi; Monik C Jiménez; Lori Chaffin Jordan; Suzanne E Judd; Daniel Lackland; Judith H Lichtman; Lynda Lisabeth; Simin Liu; Chris T Longenecker; Rachel H Mackey; Kunihiro Matsushita; Dariush Mozaffarian; Michael E Mussolino; Khurram Nasir; Robert W Neumar; Latha Palaniappan; Dilip K Pandey; Ravi R Thiagarajan; Mathew J Reeves; Matthew Ritchey; Carlos J Rodriguez; Gregory A Roth; Wayne D Rosamond; Comilla Sasson; Amytis Towfighi; Connie W Tsao; Melanie B Turner; Salim S Virani; Jenifer H Voeks; Joshua Z Willey; John T Wilkins; Jason Hy Wu; Heather M Alger; Sally S Wong; Paul Muntner Journal: Circulation Date: 2017-01-25 Impact factor: 29.690
Authors: Ioannis Kalampokis; Guglielmo M Venturi; Jonathan C Poe; Jeffrey A Dvergsten; John W Sleasman; Thomas F Tedder Journal: Arthritis Rheumatol Date: 2017-01 Impact factor: 10.995